BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT05197426
- Locations
- ๐บ๐ธ
Local Institution - 0011, Huntsville, Alabama, United States
๐ฏ๐ตLocal Institution - 0017, Nagoya, Aichi, Japan
๐ฏ๐ตLocal Institution - 0023, Nagoya, Aichi, Japan
Expanded Access for Apixaban
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05187286
- Locations
- ๐บ๐ธ
Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05170685
Expanded Access for Abatacept
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05170672
- Locations
- ๐บ๐ธ
Local Institution - 0001, Austin, Texas, United States
๐ง๐ชLocal Institution - 0002, Leuven, Vlaams-brabant, Belgium
Expanded Access for Relatlimab
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05170659
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT05169684
- Locations
- ๐บ๐ธ
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
๐จ๐ฆLocal Institution - 0028, Toronto, Ontario, Canada
๐บ๐ธThe Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- Conditions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1182
- Registration Number
- NCT05170126
- Locations
- ๐ฉ๐ช
Marienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum, Herne, Germany
๐บ๐ธEvidera, Bethesda, Maryland, United States
A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal
- Conditions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 105
- Registration Number
- NCT05168436
- Locations
- ๐ช๐ธ
Local Institution, Castellon de La Plana, Spain
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 218
- Registration Number
- NCT05168202
- Locations
- ๐บ๐ธ
Local Institution - 0001, Houston, Texas, United States
๐ฆ๐บLocal Institution - 0027, Wollongong, New South Wales, Australia
๐ฆ๐บLocal Institution - 0006, Clayton, Victoria, Australia
A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer
- Conditions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT05165264
- Locations
- ๐ฉ๐ช
Local Institution, Hamburg, Germany